[Treatment of erectile dysfunction with vacuum pumps]

Urologe A. 1993 Jul;32(4):312-5.
[Article in German]


A Vacuum constrictor device (VCD) was tested in 90 patients with organic erectile failure, some of whom had positive and some, negative responses to intracavernous self-injection of vasoactive drugs. Acceptance of the VCD overall was 37%. Among the 49 patients who did not respond to intracavernous injection of vasoactive drugs, acceptance was 45%, clearly higher than among the 41 responders to the injections, only 27% of whom accepted the VCD. Isolated subcutaneous hematomas were the only noteworthy complications observed with long-term therapy (up to 3 years). In cases of so-called venous leakage, the degree of venous outflow disturbance limited the use of the VCD, even in combination with self-injection therapy. The VCD is a successful alternative therapeutic option for the treatment of organic erectile failure, with a lower primary acceptance than corpus cavernosum self-injection therapy.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alprostadil / administration & dosage
  • Combined Modality Therapy
  • Drug Therapy, Combination
  • Erectile Dysfunction / etiology
  • Erectile Dysfunction / therapy*
  • Humans
  • Male
  • Middle Aged
  • Papaverine / administration & dosage
  • Patient Acceptance of Health Care
  • Penis / blood supply
  • Phentolamine / administration & dosage
  • Suction / instrumentation*
  • Vacuum
  • Venous Insufficiency / complications
  • Venous Insufficiency / therapy*


  • Papaverine
  • Alprostadil
  • Phentolamine